- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.08. | FDA approves Ionis' donidalorsen for HAE attack prevention | ||
| 22.08. | Gilead's Kite scoops in vivo CAR-T specialist Interius for $350m | ||
| 22.08. | Magazine: Big biopharma take on the ADC challenge | ||
| 22.08. | Andelyn and Amplo link on AAV gene therapy for NMJ conditions | ||
| 21.08. | Padcev-Keytruda combo approved for NHS use in mUC | ||
| 21.08. | Advancing rare disease trials by overcoming patient recruitment challenges | ||
| 21.08. | J&J signs $2bn incumbency deal at CDMO Fujifilm's new hub | ||
| 21.08. | Novo's facility issues delay FDA decisions on Regeneron's Eylea HD | ||
| 21.08. | Keros gains FDA orphan drug status for DMD treatment KER-065 | ||
| 21.08. | Boehringer and AnGes link on drug substance manufacture for PAD | ||
| 20.08. | Pfizer battles another Paxlovid lawsuit from Enanta | ||
| 20.08. | Madrigal wins European MASH approval as Novo rivalry looms | ||
| 20.08. | FDA awards breakthrough therapy status to BMS and SystImmune's NSCLC drug | ||
| 20.08. | PTC Therapeutics' vatiquinone approval hopes dashed in Friedreich's Ataxia | ||
| 20.08. | ashibio licences vantictumab for rare bone disorder | ||
| 19.08. | Trade-offs abound as big pharma makes direct-to-consumer transition | ||
| 19.08. | Data Points to Potential for Patient Centricity in Rare Disease Trial Success | ||
| 19.08. | CSL slashes 15% of workforce and offshoots vaccine division | ||
| 19.08. | Santen and RemeGen sign licence deal for retinal disease injection | ||
| 19.08. | Merck announces EC approval of Ogsiveo for desmoid tumours | ||
| 18.08. | Boehringer Ingelheim marks retinal disease push with $327m licensing deal | ||
| 18.08. | Accelerating diagnosis and drug development with better managed datasets | ||
| 18.08. | Novel software solutions can ease transition in an age of clinical supply chain upheaval | ||
| 18.08. | FDA approves Papzimeos as first therapy for HPV-caused airway disease | ||
| 18.08. | Wegovy becomes first GLP-1RA to gain FDA MASH approval |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .